Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AGIOthis companyAgios Pharmaceuticals, Inc.	$30.10	-3.82×	1.32×	29.21×	-3.74×	-87.2%	78.7%	-873.9%	-764.0%	-34.6%	-38.2%	-23.9%	0.03×	0.12×	0×	11.46×	0.0%	3	11.59	2	C
BCRXBioCryst Pharmaceuticals, Inc.	$7.61	6.19×	-13.74×	1.87×	5.71×	-1611.4%	97.8%	39.0%	30.2%	-221.4%	105.2%	20.0%	-3.68×	1×	4.32×	2.06×	0.0%	5	-3.69	2	B-
IRONDisc Medicine, Inc.	$79.57	-13.21×	3.79×	0×	-13.05×	-97.1%	0.0%	0.0%	0.0%	-28.7%	-30.6%	-6.5%	0×	0.43×	-65.43×	21.94×	0.0%	1	18.78	2	C
MIRMMirum Pharmaceuticals, Inc.	$92.63	-168.06×	12.6×	7.61×	231.78×	-3770.3%	80.7%	-4.2%	-4.5%	-7.4%	-3.5%	1.4%	1.02×	1.32×	-1.54×	2.67×	0.0%	3	-0.33	2	C
PTCTPTC Therapeutics, Inc.	$64.46	8.85×	-29.43×	3.49×	8.75×	-1377.4%	95.9%	49.5%	39.4%	-332.5%	33.4%	6.8%	-13.19×	1.94×	5.63×	2.35×	0.0%	4	0.75	2	C
RAREUltragenyx Pharmaceutical Inc.	$15.69	-3.95×	-28.35×	3.37×	-6.56×	-2636.3%	83.8%	-79.5%	-85.4%	718.8%	-43.5%	-20.8%	-15.95×	-1.78×	-8.63×	2.48×	0.0%	2	-5.22	2	B-
Peer median	—	-3.95×	-13.74×	3.37×	5.71×	-1611.4%	83.8%	0.0%	0.0%	-28.7%	-3.5%	1.4%	-3.68×	1×	-1.54×	2.48×	0.0%	3	-0.33	2	—